Inactive Instrument

Cardiovascular Systems, Inc.

CSII

US1416191062

Medical Equipment, Supplies & Distribution

CARDIOVASCULAR SYSTEMS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

February 05, 2020 at 04:15 pm EST

Item 2.02. Results of Operations and Financial Condition.



On February 5, 2020, Cardiovascular Systems, Inc. (the "Company") issued a press
release regarding the Company's financial results for its second fiscal quarter
ended December 31, 2019, and posted on its website its Q2 FY20 Earnings Call
Presentation, which contains certain additional historical and forward-looking
information relating to the Company. A copy of the Company's press release is
attached hereto as Exhibit 99.1 and a copy of the presentation is attached
hereto as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.



(d)   Exhibits



Exhibit
Number                                                                                         Description

       99.1                                                                                      Press
                                                                                               Release dated
                                                                                               February 5,
                                                                                               2020

       99.2               Q2 FY20 Earnings Call Presentation

--------------------------------------------------------------------------------

Latest news about Cardiovascular Systems, Inc.

Orbusneich Medical Group Holdings Limited and Cardiovascular Systems, Inc. Enters into an Amendment to Distribution Agreement	23-09-27	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Healthcare Equipment Select Industry Index	23-05-01	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Composite 1500	23-05-01	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 600	23-05-01	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Global BMI Index	23-05-01	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 1000	23-05-01	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P TMI Index	23-05-01	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 600 Health Care	23-05-01	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from NASDAQ Composite Index	23-04-27	CI
Abbott Laboratories completed the acquisition of Cardiovascular Systems, Inc. from The Vanguard Group, Inc. and others.	23-04-26	CI
Wall St dips as Treasury yields rise after auction	23-02-09	RE
Wall St dips as Treasury yields rise after auction	23-02-09	RE
Wall St dips as Treasury yields rise; Disney hits 5-month high	23-02-09	RE
Top Midday Gainers	23-02-09	MT
Wall St dips as Alphabet extends fall; Disney hits 5-month high	23-02-09	RE
Sector Update: Health Care Stocks Mixed Premarket Thursday	23-02-09	MT
Top Premarket Gainers	23-02-09	MT
Abbott Laboratories Enters Deal to Acquire Cardiovascular Systems for $890 Million	23-02-09	MT
North American Morning Briefing : Stocks Seen -2-	23-02-09	DJ
North American Morning Briefing : Stocks Seen Bouncing Back, Next Catalysts Eyed	23-02-09	DJ
Cardiovascular Systems Shares Soar Premarket on Abbott Buyout	23-02-09	DJ
Cardiovascular Systems Fiscal Q2 Loss, Revenue Increases; Shares Rise Pre-Bell	23-02-09	MT
EMEA Morning Briefing : Investors to Parse Fed -2-	23-02-09	DJ
Abbott Laboratories to Acquire Cardiovascular Systems At Equity Value of $890 Million	23-02-08	DJ
Cardiovascular Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-08	CI

Chart Cardiovascular Systems, Inc.

Duration

Period

More charts

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its peripheral artery disease (PAD) products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-2.31%	185B
MEDTRONIC PLC	-3.20%	105B
BECTON, DICKINSON AND COMPANY	-5.04%	66.59B
DEXCOM, INC.	+0.20%	54.66B
CENCORA, INC.	+17.29%	47.78B
HOYA CORPORATION	+4.06%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.37B
TERUMO CORPORATION	+12.96%	24.8B

Other Medical Equipment, Supplies & Distribution